Brigid Bio, a biotech spin-out from the University of Aberdeen, has secured $150,000 in investment capital from investors. This funding round supports the company's efforts in developing novel therapeutic solutions for high-risk and drug-resistant fungal infections, an area with significant unmet medical need.
The company specializes in creating first-in-class antibody-based drugs, aiming to provide safer and more efficacious treatment options. Brigid Bio has established a unique and proprietary drug discovery platform, through which it has identified key fungal pathogen-specific cell wall markers as novel drug targets. Its lead human monoclonal antibodies targeting these markers have demonstrated efficacy in a clinically predictive in vivo infection model.
This investment will be crucial in advancing Brigid Bio鈥檚 research and development initiatives. The capital is planned to support further preclinical development of its lead drug candidates and to enhance its proprietary drug discovery platform. The funding signifies an important step for the company as it progresses towards bringing its innovative treatments closer to patients battling severe fungal infections.
Brigid Bio is led by a team recognized for its global scientific expertise and commercial experience, and it is supported by the Scottish Enterprise High Growth Spinout Programme. The company continues its work with a focus on addressing critical medical challenges. This funding positions Brigid Bio to further validate its technology and advance its pipeline, contributing to the development of new treatments for life-threatening fungal diseases.
.png&w=3840&q=75)
